298380.KQ
ABL Bio Inc.
1W: -5.3%
1M: -5.3%
3M: +84.5%
YTD: -3.2%
1Y: +384.9%
3Y: +704.9%
₩179,800.00 ($119.50)
-100.00 (-0.06%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap₩9.92T ($6.6B)
52W Range31300-257500
Volume350,205
Avg Volume1,092,510
Beta0.47
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOSang Hoon Lee
Employees102
SectorHealthcare
IndustryMedical - Pharmaceuticals
IPO Date2018-12-19
Websiteablbio.com
16 Daewangpangyo-Ro 712 Beon-Gil
Seongnam 13488
KR
Seongnam 13488
KR
82 31 8018 9800
About ABL Bio Inc.
ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. The company is headquartered in Seongnam, South Korea.
Latest News
No recent news
Recent Insider Trades
No insider trades found